Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥18 and ≤55 years of age~* Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm~* Body mass index (BMI) ≥18 and ≤35 kg/sq m~* Able to provide written informed consent~Exclusion Criteria:~* Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 5 days of dosing~* Use of any investigational agent or study treatment within 30 days of Day 1~* Use of any protein or antibody-based therapeutic agents within 3 months of Screening~* Prior exposure to any SGLT inhibitor~* Use of cigarettes or any tobacco products within 6 weeks prior to Screening and while participating in the study~* History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption~* History of any major surgery within 6 months of Screening~* History of any hypersensitivity to the inactive components of LX4211~* History of renal disease or significantly abnormal kidney function tests~* History of hepatic disease or significantly abnormal liver function tests~* History of any active infection within 30 days of Day 1~* History of alcohol or substance abuse within 2 years prior to Day 1~* Positive urine glucose at Screening~* Positive pregnancy test at Screening~* Inability or difficulty swallowing whole tablets or capsules~* Unable or unwilling to communicate or cooperate with the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- LX4211 (Type: EXPERIMENTAL): 400 mg of LX4211 administered orally
- Placebo (Type: PLACEBO_COMPARATOR): Nonidentical placebo administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).